Tags

Type your tag names separated by a space and hit enter

Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
Cancer. 2005 Oct 15; 104(8):1580-9.C

Abstract

BACKGROUND

The objective of this study was to compare the quality of life (QOL) after treatment among patients who had breast carcinoma with multiple positive lymph nodes. The patients were randomized to receive either high-dose chemotherapy with autologous stem cell support (HDC) or intermediate-dose chemotherapy (IDC) in the adjuvant setting.

METHODS

Two hundred forty-six patients with AJCC Stage IIA, IIB, or IIIA breast carcinoma who had > or = 10 positive lymph nodes and who were participants in Cancer and Leukemia Group B (CALGB) 9082 were enrolled in this companion study, CALGB 9066. Patients were randomized to receive either high-dose cyclophosphamide, carmustine, and cisplatin (CPA/cDDP/BCNU) and autologous bone marrow transplantation (the HDC arm) or intermediate-dose CPA/cDDP/BCNU as consolidation to adjuvant chemotherapy (the IDC arm). QOL was assessed at baseline and at 3 months, 12 months, 24 months, and 36 months using the Functional Living Index-Cancer (FLIC), the Psychosocial Adjustment to Illness Scale (PAIS)-Self Report, and the McCorkle Symptom Distress Scale (SDS).

RESULTS

At the 3-month assessment, patients in the HDC arm demonstrated significant worsening of QOL compared with the IDC arm in terms of their physical well being (FLIC, P = 0.023), social functioning (FLIC, P = 0.026; PAIS, P < 0.0001), symptom distress (SDS, P = 0.0002), and total QOL scores (FLIC, P = 0.042). At 12 months, the differences in QOL scores between the HDC arm and the IDC arm had resolved.

CONCLUSIONS

Patients who received more intensive adjuvant therapy experienced transient declines in QOL. By 12 months after therapy, QOL was comparable between the 2 arms, regardless of therapy intensity, and many QOL areas were improved from baseline.

Authors+Show Affiliations

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

16118805

Citation

Peppercorn, Jeffrey, et al. "Quality of Life Among Patients With Stage II and III Breast Carcinoma Randomized to Receive High-dose Chemotherapy With Autologous Bone Marrow Support or Intermediate-dose Chemotherapy: Results From Cancer and Leukemia Group B 9066." Cancer, vol. 104, no. 8, 2005, pp. 1580-9.
Peppercorn J, Herndon J, Kornblith AB, et al. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer. 2005;104(8):1580-9.
Peppercorn, J., Herndon, J., Kornblith, A. B., Peters, W., Ahles, T., Vredenburgh, J., Schwartz, G., Shpall, E., Hurd, D. D., Holland, J., & Winer, E. (2005). Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer, 104(8), 1580-9.
Peppercorn J, et al. Quality of Life Among Patients With Stage II and III Breast Carcinoma Randomized to Receive High-dose Chemotherapy With Autologous Bone Marrow Support or Intermediate-dose Chemotherapy: Results From Cancer and Leukemia Group B 9066. Cancer. 2005 Oct 15;104(8):1580-9. PubMed PMID: 16118805.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. AU - Peppercorn,Jeffrey, AU - Herndon,James,2nd AU - Kornblith,Alice B, AU - Peters,William, AU - Ahles,Tim, AU - Vredenburgh,James, AU - Schwartz,Gary, AU - Shpall,Elizabeth, AU - Hurd,David D, AU - Holland,Jimmie, AU - Winer,Eric, PY - 2005/8/25/pubmed PY - 2006/1/13/medline PY - 2005/8/25/entrez SP - 1580 EP - 9 JF - Cancer JO - Cancer VL - 104 IS - 8 N2 - BACKGROUND: The objective of this study was to compare the quality of life (QOL) after treatment among patients who had breast carcinoma with multiple positive lymph nodes. The patients were randomized to receive either high-dose chemotherapy with autologous stem cell support (HDC) or intermediate-dose chemotherapy (IDC) in the adjuvant setting. METHODS: Two hundred forty-six patients with AJCC Stage IIA, IIB, or IIIA breast carcinoma who had > or = 10 positive lymph nodes and who were participants in Cancer and Leukemia Group B (CALGB) 9082 were enrolled in this companion study, CALGB 9066. Patients were randomized to receive either high-dose cyclophosphamide, carmustine, and cisplatin (CPA/cDDP/BCNU) and autologous bone marrow transplantation (the HDC arm) or intermediate-dose CPA/cDDP/BCNU as consolidation to adjuvant chemotherapy (the IDC arm). QOL was assessed at baseline and at 3 months, 12 months, 24 months, and 36 months using the Functional Living Index-Cancer (FLIC), the Psychosocial Adjustment to Illness Scale (PAIS)-Self Report, and the McCorkle Symptom Distress Scale (SDS). RESULTS: At the 3-month assessment, patients in the HDC arm demonstrated significant worsening of QOL compared with the IDC arm in terms of their physical well being (FLIC, P = 0.023), social functioning (FLIC, P = 0.026; PAIS, P < 0.0001), symptom distress (SDS, P = 0.0002), and total QOL scores (FLIC, P = 0.042). At 12 months, the differences in QOL scores between the HDC arm and the IDC arm had resolved. CONCLUSIONS: Patients who received more intensive adjuvant therapy experienced transient declines in QOL. By 12 months after therapy, QOL was comparable between the 2 arms, regardless of therapy intensity, and many QOL areas were improved from baseline. SN - 0008-543X UR - https://www.unboundmedicine.com/medline/citation/16118805/Quality_of_life_among_patients_with_Stage_II_and_III_breast_carcinoma_randomized_to_receive_high_dose_chemotherapy_with_autologous_bone_marrow_support_or_intermediate_dose_chemotherapy:_results_from_Cancer_and_Leukemia_Group_B_9066_ L2 - https://doi.org/10.1002/cncr.21363 DB - PRIME DP - Unbound Medicine ER -